During the last session, Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s traded shares were 0.52 million, with the beta value of the company hitting 1.59. At the end of the trading day, the stock’s price was $2.27, reflecting an intraday loss of -10.12% or -$0.25. The 52-week high for the SYRS share is $8.17, that puts it down -259.91 from that peak though still a striking 37.0% gain since the share price plummeted to a 52-week low of $1.43. The company’s market capitalization is $60.72M, and the average intraday trading volume over the past 10 days was 0.7 million shares, and the average trade volume was 419.14K shares over the past three months.

Syros Pharmaceuticals Inc (SYRS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. SYRS has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.74.

Syros Pharmaceuticals Inc (NASDAQ:SYRS) trade information

Syros Pharmaceuticals Inc (SYRS) registered a -10.12% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -10.12% in intraday trading to $2.27, hitting a weekly high. The stock’s 5-day price performance is 13.25%, and it has moved by 16.75% in 30 days. Based on these gigs, the overall price performance for the year is -5.23%. The short interest in Syros Pharmaceuticals Inc (NASDAQ:SYRS) is 0.95 million shares and it means that shorts have 4.74 day(s) to cover.

The consensus price target of analysts on Wall Street is $15, which implies an increase of 84.87% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $30 respectively. As a result, SYRS is trading at a discount of -1221.59% off the target high and -120.26% off the low.

Syros Pharmaceuticals Inc (SYRS) estimates and forecasts

Statistics show that Syros Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Syros Pharmaceuticals Inc (SYRS) shares have gone down -55.85% during the last six months, with a year-to-date growth rate more than the industry average at 51.91% against 17.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 66.10% this quarter and then drop -650.00% in the quarter after that. In the rating firms’ projections, revenue will decrease -95.50% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 450k as predicted by 4 analyst(s). As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 387k and 720k respectively.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 21.16%. While earnings are projected to return 72.91% in 2024.

SYRS Dividends

Syros Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-Mar-25. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s Major holders

Syros Pharmaceuticals Inc insiders own 1.32% of total outstanding shares while institutional holders control 81.06%, with the float percentage being 82.15%.